nach oben

Surgery Today

Erschienen in:

04.08.2021 | Review Article

Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes

verfasst von: Akira Iyoda, Yoko Azuma, Susumu Sakamoto, Sakae Homma, Atsushi Sano

Erschienen in: Surgery Today | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Postoperative exacerbation of interstitial pneumonia in patients with interstitial lung disease and lung cancer has emerged as a serious problem. Therefore, we need to determine the risk factors for the development of postoperative exacerbation of interstitial pneumonia in this population. There are several subtypes of interstitial lung disease, which may lead to confusion about the treatment of patients with interstitial lung disease and lung cancer. Among the idiopathic forms of interstitial lung disease, we focused on idiopathic pulmonary fibrosis (IPF) and reviewed the surgical treatments used for patients with IPF and lung cancer.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.PubMed

Masuda M, Kuwano H, Okumura M, Amano J, Arai H, Endo S, Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, et al. Thoracic and cardiovascular surgery in Japan during 2012: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2014;62:734–64.PubMedPubMedCentral

Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–23.PubMed

American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304.

Saito A, Horie M, Micke P, Nagase T. The role of TGF-β signaling in lung cancer associated with idiopathic pulmonary fibrosis. Int J Mol Sci. 2018;19:3611.PubMedCentral

Ballester B, Milara J, Cortijo J. Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets. Int J Mol Sci. 2019;20:593.PubMedCentral

King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–61.PubMed

Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D. Common pathogenic mechanisms between idiopathic pulmonary fibrosis and lung cancer. Chest. 2019;156:383–91.PubMed

Kutlu CA, Williams EA, Evans TW, Pastorino U, Goldstraw P. Acute lung injury and acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg. 2000;69:376–80.PubMed

10.

Ruffini E, Parola A, Papalia E, Filosso PL, Mancuso M, Oliaro A, et al. Frequency and mortality of acute lung injury and acute respiratory distress syndrome after pulmonary resection for bronchogenic carcinoma. Eur J Cardiothorac Surg. 2001;20:30–6.PubMed

11.

Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, Japanese Association for Chest Surgery, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147:1604–11.PubMed

12.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.PubMedPubMedCentral

13.

Watanabe A, Miyajima M, Mishina T, Nakazawa J, Harada R, Kawaharada N, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg. 2013;61:254–61.PubMed

14.

Miura Y, Saito T, Tanaka T, Takoi H, Yatagai Y, Inomata M, et al. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Investig. 2018;56:72–9.PubMed

15.

Yoo H, Jeong BH, Chung MJ, Lee KS, Kwon OJ, Chung MP. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2019;19:149.PubMedPubMedCentral

16.

Kawasaki H, Nagai K, Yokose T, Yoshida J, Nishimura M, Takahashi K, et al. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 2001;76:53–7.PubMed

17.

Calabrese F, Lunardi F, Balestro E, Marulli G, Perissinotto E, Loy M, et al. Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis. Pathology. 2012;44:192–8.PubMed

18.

Homma S, Sugino K, Sakamoto S. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respir Investig. 2015;53:7–12.PubMed

19.

Sato T, Kondo H, Watanabe A, Nakajima J, Niwa H, Horio H, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg. 2015;63:164–7.PubMed

20.

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.PubMed

21.

Otsuka H, Sugino K, Hata Y, Makino T, Koezuka S, Isobe K, et al. Clinical features and outcomes of patients with lung cancer as well as combined pulmonary fibrosis and emphysema. Mol Clin Oncol. 2016;5:273–8.PubMedPubMedCentral

22.

Iyoda A, Jiang SX, Amano H, Ogawa F, Matui Y, Kurouzu N, et al. Prediction of postoperative exacerbation of interstitial pneumonia in patients with lung cancer and interstitial lung disease. Exp Ther Med. 2011;2:1073–6.PubMedPubMedCentral

23.

Chiyo M, Sekine Y, Iwata T, Tatsumi K, Yasufuku K, Iyoda A, et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg. 2003;126:1141–6.PubMed

24.

Kinoshita T, Azuma K, Sasada T, Okamoto M, Hattori S, Imamura Y, et al. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett. 2012;4:477–82.PubMedPubMedCentral

25.

Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013;85:326–31.PubMed

26.

Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260–5.PubMed

27.

Nagano T, Kotani Y, Fujii O, Demizu Y, Niwa Y, Ohno Y, et al. A case of acute exacerbation of idiopathic pulmonary fibrosis after proton beam therapy for non-small cell lung cancer. Jpn J Clin Oncol. 2012;42:965–9.PubMed

28.

Miyamoto T, Yamamoto N, Nishimura H, Koto M, Tsujii H, Mizoe JE, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2003;66:127–40.PubMed

29.

Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018;56:268–91.PubMed

30.

Tanaka K, Tsutani Y, Wakabayashi M, Mizutani T, Aokage K, Miyata Y, Behalf of the Lung Cancer Surgical Study Group/Japan Clinical Oncology Group, et al. Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, SURPRISE). Jpn J Clin Oncol. 2020;50:1076–9.PubMed

31.

Sato T, Watanabe A, Kondo H, Kanzaki M, Okubo K, Yokoi K, Japanese Association for Chest Surgery, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015;149:64–9.PubMed

32.

Sato S, Shimizu Y, Goto T, Kitahara A, Koike T, Ishikawa H, et al. Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study. BMC Pulm Med. 2018;18:134.PubMedPubMedCentral

33.

Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg. 2008;136:1357–63.PubMed

34.

Saito Y, Kawai Y, Takahashi N, Ikeya T, Murai K, Kawabata Y, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92:1812–7.PubMed

35.

Suzuki H, Sekine Y, Yoshida S, Suzuki M, Shibuya K, Yonemori Y, et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today. 2011;41:914–21.PubMed

36.

Mizuno Y, Iwata H, Shirahashi K, Takamochi K, Oh S, Suzuki K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41:e161–5.PubMed

37.

Iwata T, Yoshida S, Nagato K, Nakajima T, Suzuki H, Tagawa T, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today. 2015;45:1263–70.PubMed

38.

Iwata T, Yoshida S, Fujiwara T, Wada H, Nakajima T, Suzuki H, et al. Effect of perioperative pirfenidone treatment in lung cancer patients with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2016;102:1905–10.PubMed

39.

Iwata T, Yoshino I, Yoshida S, Ikeda N, Tsuboi M, Asato Y, West Japan Oncology Group, et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE study). Respir Res. 2016;17:90.PubMedPubMedCentral

40.

Sekihara K, Aokage K, Miyoshi T, Tane K, Ishii G, Tsuboi M. Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis. Surg Today. 2020;50:905–11.PubMed

41.

Kanayama M, Mori M, Matsumiya H, Taira A, Shinohara S, Kuwata T, et al. Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. Surg Today. 2020;50:469–74.PubMed

42.

Sakamoto S, Homma S, Mun M, Fujii T, Kurosaki A, Yoshimura K. Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. Intern Med. 2011;50:77–85.PubMed

43.

Watanabe A, Kawaharada N, Higami T. Postoperative acute exacerbation of IPF after lung resection for primary lung cancer. Pulm Med. 2011;2011:960316.PubMedPubMedCentral

44.

Furuya K, Sakamoto S, Takai Y, Sato N, Matsumoto K, Homma S. Acute exacerbation of idiopathic interstitial pneumonia after nonpulmonary surgery under general anesthesia: a retrospective study. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34:156–64.PubMedPubMedCentral

45.

Koyama K, Sakamoto S, Isshiki T, Shimizu H, Kurosaki A, Homma S. The activities of daily living after an acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2017;56:2837–43.PubMedPubMedCentral

46.

Isobe K, Kaburaki K, Kobayashi H, Sano G, Sakamoto S, Takai Y, et al. New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia. Lung Cancer. 2018;125:253–7.PubMed

47.

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, CAPACITY Study Group, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.PubMed

48.

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fbrosis. N Engl J Med. 2014;370:2083–92.PubMed

49.

Sakamoto S, Shimizu H, Isshiki T, Nakamura Y, Kurosaki A, Isobe K, et al. Effectiveness of pirfenidone for idiopathic pulmonary fibrosis associated with pleuroparenchymal fibroelastosis-like lesions and nonspecific interstitial pneumonia. Clin Respir J. 2020. https://doi.org/10.1111/crj.13292.CrossRefPubMed

50.

Sakamoto S, Muramatsu Y, Satoh K, Ishida F, Kikuchi N, Sano G, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology. 2015;20:445–52.PubMed

51.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, INPULSIS Trial Investigators, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.PubMed

52.

Bronte G, Passiglia F, Galvano A, Barraco N, Listì A, Castiglia M, et al. Nintedanib in NSCLC: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8:188–97.PubMedPubMedCentral

53.

Fukunaga K, Yokoe S, Kawashima S, Uchida Y, Nakagawa H, Nakano Y. Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis. Respirol Case Rep. 2018;6:e00363.PubMedPubMedCentral

54.

Shiratori T, Tanaka H, Tabe C, Tsuchiya J, Ishioka Y, Itoga M, et al. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: a case report and literature review. Thorac Cancer. 2020;11:1720–3.PubMedPubMedCentral

55.

Yamauchi Y, Izumi Y, Inoue M, Sugiura H, Goto T, Anraku M, et al. Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. PLoS ONE. 2011;6:e29053.PubMedPubMedCentral

56.

Kondoh Y, Azuma A, Inoue Y, Ogura T, Sakamoto S, Tsushima K, et al. Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. A randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2020;201:1110–9.PubMed

57.

Isshiki T, Sakamoto S, Homma S. Therapeutic role of recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis. Medicina (Kaunas). 2019;55:172.

58.

Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration. 2015;89:201–7.PubMed

59.

Goto T, Maeshima A, Akanabe K, Oyamada Y, Kato R. Acute exacerbation of idiopathic pulmonary fibrosis of microscopic usual interstitial pneumonia pattern after lung cancer surgery. Ann Thorac Cardiovasc Surg. 2011;17:573–6.PubMed

60.

Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K, Homma S. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology. 2010;15:88–92.PubMed

61.

Sakamoto S, Shimizu H, Isshiki T, Sugino K, Kurosaki A, Homma S. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a historically controlled study. Respir Investig. 2018;56:136–43.PubMed

62.

Furuya K, Sakamoto S, Shimizu H, Sekiya M, Kinoshita A, Isshiki T, et al. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respir Med. 2017;126:93–9.PubMed

63.

Fujimoto T, Okazaki T, Matsukura T, Hanawa T, Yamashita N, Nishimura K, et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication? Ann Thorac Surg. 2003;76:1674–8.PubMed

Titel: Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes
verfasst von: Akira Iyoda
Yoko Azuma
Susumu Sakamoto
Sakae Homma
Atsushi Sano
Publikationsdatum: 04.08.2021
Verlag: Springer Nature Singapore
Erschienen in: Surgery Today / Ausgabe 5/2022
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-021-02343-0

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

The prediction of postoperative anorectal dysfunction after low anterior resection for lower rectal cancer by measuring the volume of defecation-related muscles

Comparison of mid-term effectiveness and safety of one-anastomosis gastric bypass and sleeve gastrectomy in patients with super obesity (BMI ≥ 50 kg/m2)

The evaluation of the postoperative quality of life in patients undergoing radical gastrectomy for esophagogastric junction cancer using the Postgastrectomy Syndrome Assessment Scale-45: a nationwide multi-institutional study

A prognostic model for 1-month mortality in the postoperative intensive care unit

Vascular anatomy of the splenic flexure: a review of the literature

The type of gastrectomy affects skeletal muscle loss and the long-term outcomes of elderly patients with gastric cancer: a retrospective study using computed tomography images

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“